Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Sells $73,246.50 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 3,690 shares of the firm’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the sale, the insider now directly owns 55,937 shares in the company, valued at $1,110,349.45. This trade represents a 6.19 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Nurix Therapeutics Stock Performance

NRIX traded up $0.36 during trading on Thursday, reaching $20.01. The company’s stock had a trading volume of 695,140 shares, compared to its average volume of 662,076. The company’s fifty day moving average price is $20.14 and its 200-day moving average price is $22.40. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -6.88 and a beta of 2.14. Nurix Therapeutics, Inc. has a 52-week low of $7.79 and a 52-week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. Equities analysts predict that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on NRIX. Royal Bank of Canada boosted their price objective on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday. BMO Capital Markets initiated coverage on shares of Nurix Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $35.00 price objective for the company. Jefferies Financial Group assumed coverage on Nurix Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $41.00 target price on the stock. HC Wainwright upped their target price on Nurix Therapeutics from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Stephens reaffirmed an “overweight” rating and set a $31.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, Nurix Therapeutics has an average rating of “Moderate Buy” and an average price target of $30.71.

Institutional Trading of Nurix Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Amalgamated Bank lifted its position in shares of Nurix Therapeutics by 30.6% during the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after acquiring an additional 511 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Nurix Therapeutics by 31.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock worth $54,000 after purchasing an additional 559 shares during the last quarter. Quarry LP boosted its position in Nurix Therapeutics by 3,746.2% during the third quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $56,000 after purchasing an additional 2,435 shares in the last quarter. International Assets Investment Management LLC grew its holdings in Nurix Therapeutics by 1,098.4% in the third quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock valued at $101,000 after purchasing an additional 4,119 shares during the last quarter. Finally, Quest Partners LLC increased its position in shares of Nurix Therapeutics by 21.3% in the third quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock valued at $168,000 after buying an additional 1,312 shares in the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.